| 前列腺癌骨转移患者血清中卵泡抑制素样蛋白1的表达及临床相关性研究 |
| |
| 引用本文： | 丁涛,;何小舟,;许贤林,;徐海燕,;周萃星,;王禹基. 前列腺癌骨转移患者血清中卵泡抑制素样蛋白1的表达及临床相关性研究[J]. 中华男科学杂志, 2014, 0(12): 1090-1092 |
| |
| 作者姓名： | 丁涛, 何小舟, 许贤林, 徐海燕, 周萃星, 王禹基 |
| |
| 作者单位： | [1]苏州大学附属第三医院泌尿外科,江苏常州213003; [2]南京医科大学附属常州第二医院骨科,江苏常州213003 |
| |
| 摘 要： | 目的:探讨卵泡抑素样蛋白1(FSTL1)在前列腺癌骨转移患者中的表达,以及血清FSTL1与机体慢性炎性因子白介素6(IL-6)、细胞生长分化调节相关因子骨形成蛋白6(BMP6)的相关性,探讨血清FSTL1对前列腺癌骨转移的临床应用价值。方法:采用ELISA法测定35例前列腺癌骨转移患者和30例良性前列腺增生(BPH)患者血清FSTL1、IL-6、BMP6水平,并进行相关性分析。结果:前列腺癌骨转移组血清FSTL1的表达水平[(20.23±8.69)μg/L]较BPH组[(35.45±12.35)μg/L]明显降低(P0.01);血清IL-6、BMP6表达[(23.56±20.17)μg/L、(428.30±178.40)μg/L]较BPH组[(11.21±8.62)μg/L、(293.50±39.72)μg/L]明显增高(P0.05);前列腺癌骨转移组的血清FSTL1的表达与IL-6、BMP6呈显著负相关,相关系数分别为-0.971、-0.972(P0.05)。结论:前列腺癌骨转移患者血清FSTL1的表达降低,并且和体内炎症因子、细胞转化因子有关,为临床判断前列腺癌的发生及进展提供了新的生物学标记,为前列腺癌治疗提供了新的生物学靶向分子。
|
| 关 键 词： | 前列腺癌,骨转移 卵泡抑制素样蛋白1 白介素6 骨形成蛋白6 |
Expression of serum FSTL-1 in bone metastasis of prostate cancer and its clinical implication |
| |
| Affiliation: | DING Tao , HE Xiao-zhou , XU Xian-lin , XU Hai-yan , ZHOU Cui-xing , WANG Yu-ji( 1. Department of Urology, The Third Hospital of Soochow University, Changzhou, Jiangsu 213003, China; 2. Department of Orthopedics, Changzhou Second Hospital Affiliated to Nanjing Medical University, Changzhou, Jiangsu 213003, China) |
| |
| Abstract: | Objective ： To investigate the expression of follistatin-like protein 1 （ FSTL-1 ） in bone metastasis of prostate cancer （BMPC） , the correlation of serum FSTL-1 with the chronic inflammatory factor interleukin-6 （IL-6） and bone morphogenetic protein 6 （BMP6） , and the clinical application value of serum FSTL-1 in BMPC. Methods ： Using ELISA, we measured the expression levels of serum FSTL-I, 1L-6, and BMP6 in 35 patients with BMPC and another 30 with benign prostatic hyperplasia （BPH） and performed correlation analysis on the data obtained. Results： Compared with the BPH controls, the BMPC patients showed a significantly decreased expression of serum FSTL-1 （ [ 34.45 ± 12.35 ] μg/L vs [ 20.23 ± 8.69 ] μg/L, P 〈 0.01 ） and increased levels of IL-6 （ [11.21 ±8.62] μg/L vs [23.56 ±20.12] μg/L, P〈0.05） and BMP6 （ [293.50 ±39.72] μg/L vs [428.30 ±178.40] μg/L, P 〈 0.05 ）. There was a significant negative correlation between the level of serum FSTL-1 and those of IL-6 and BMP6 in the BMPC patients, with correlation coefficients of -0. 971 and -0. 972, respectively （P 〈0.05）. Conclusion： The expression of serum FSTL-1 decreases in patients with bone metastasis of prostate cancer, and it is correlated with the levels of inflammatory factor and cell transformation factor. This finding offers a novel biological marker for the development and progression of prostate cancer as well as a new biological target factor for its intervention. |
| |
| Keywords: | prostate cancer bone metastatsis follistatin-like protein 1 interleukin-6 bone morphogenetic protein 6 |
| 本文献已被 CNKI 维普 等数据库收录！ |
|
